Cairo, Egypt - On February 14, 2025, Zhang Ji, Founder of Shenzhen PRO HITU Medical Co., Ltd. and President of Shenzhen Shengke Biomedical Research Institute, was invited to attend the National Institute of Liver Cancer Conference 2025 and delivered an online keynote speech entitled "Breakthrough in tissue ablation with Histotripsy in HIFU", discussing the cutting-edge progress and future directions in the field of liver tumor treatment with top experts and scholars worldwide.

The National Institute of Liver Cancer Conference 2025 is one of the most influential academic conferences in the field of liver cancer treatment in Egypt and even the whole Middle East, attracting hundreds of medical experts, scholars and industry representatives from all over the world to participate. As a representative of Chinese non-invasive medical enterprises, PRO HITU Medical was invited to attend the conference, which fully reflects the international influence of China's non-invasive medical technology.

In his speech, Zhang Ji introduced in detail the research and development process, technical advantages and clinical application effects of PRO HITU Medical's HIFU Histotripsy technology in liver tumor treatment. He pointed out that HIFU Histotripsy technology, as a new type of non-invasive tissue ablation technology, has the characteristics of non-invasive, precise, safe and effective, which can effectively solve the problems of traditional liver tumor treatment such as large trauma, high risk and slow recovery, and bring new hope to liver tumor patients.

After the speech, many experts and scholars at the conference had in-depth exchanges and discussions with Zhang Ji on the application of HIFU technology in liver tumor treatment. 

Everyone highly recognized the technical advantages and clinical value of PRO HITU Medical's HIFU technology, and expressed their willingness to carry out in-depth cooperation with PRO HITU Medical in the future to jointly promote the progress of global liver tumor treatment technology.